EUVIMEDEUVIMED entdecken
Open Access

The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer

Qian Wang, Ming Zhang, Qi-Yu Zhu, Hong Zeng, Jin-Dong Dai, Ke Huang, Si-Cheng Wan, Yi-Fu Shi, Xing-Ming Zhang, Hao Zeng, Peng-Fei Shen

Asian Journal of Andrology · 2026

DOI: 10.4103/aja202520 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asian Journal of Andrology, 2026. Verfasst von Qian Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Androstenes. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To evaluate the prognostic significance of prostate-specific antigen (PSA) decline depth and duration in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC) undergoing abiraterone treatment. We retrospectively analyzed data from 153 high-risk patients with mHSPC receiving first-line abiraterone therapy. Patients were stratified based on PSA dynamics during treatment. Kaplan–Meier survival analysis and Cox proportional hazards regression were used to assess the associations between PSA decline patterns, PSA progression-free survival (PSA-PFS), radiographic PFS (rPFS), and overall survival (OS). Among the 153 patients, 85 exhibited PSA nadir 4 ng ml −1 . During abiraterone treatment, PSA nadir

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic NeoplasmsAndrostenesHumansMalePrognosisRetrospective StudiesAgedMiddle AgedAged, 80 and overProgression-Free Survival

Stichwörter der Autor:innen

PSAdynamicshigh-riskprognosticprostate cancer

Substanzen

Prostate-Specific AntigenabirateroneAndrostenes

Autor:innen und Institutionen

  • Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.

Zitieren

APA

Wang, Q., Zhang, M., Zhu, Q. Y., Zeng, H., Dai, J. D., Huang, K., Wan, S. C., Shi, Y. F., Zhang, X. M., Zeng, H., & Shen, P. F. (2026). The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer. Asian Journal of Andrology. https://doi.org/10.4103/aja202520

Vancouver

Wang Q, Zhang M, Zhu QY, Zeng H, Dai JD, Huang K, et al. The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer. Asian Journal of Andrology. 2026. doi:10.4103/aja202520

BibTeX
@article{Wang2026,
  author = {Wang, Qian and Zhang, Ming and Zhu, Qi-Yu and Zeng, Hong and Dai, Jin-Dong and Huang, Ke and Wan, Si-Cheng and Shi, Yi-Fu and Zhang, Xing-Ming and Zeng, Hao and Shen, Peng-Fei},
  title = {The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer},
  journal = {Asian Journal of Andrology},
  year = {2026},
  doi = {10.4103/aja202520}
}
Kostenlos starten →